COVID-19 Vaccine creator Pfizer is set to close a deal to purchase drugmaker Global Blood Therapeutics. The company manufactures a recently approved drug against sickle-cell anemia. The American drug company is reportedly in talks to buy GBT for a whopping $5 billion.
Pfizer, one of the top makers of Covid-19 vaccines, hopes to conclude talks with GBT within days, said reports on Friday.
GBT’s anemia treatment, marketed as Oxbryta, was authorized for those over 12 years old in 2019 but gained federal approval only in December for children aged four to 11.
Sales of the sickle-cell treatment helped the laboratory generate a turnover of $55 million in the first-quarter, while the company registered a net loss of $81.4 million.
The company is based in San Francisco and is set is to publish its second-quarter numbers on Monday.
Pfizer, for its part, saw its second-quarter turnover jump by 47 percent to a record $27.74 billion, boosted by sales of its popular Covid vaccine.
Its net profit soared by 78 percent, to $9.9 billion. Meanwhile, GBT shares on the New York Stock Exchange were up about 33 percent at the close on Friday, at $63.84, for a market capitalization of more than $4 billion.
Must Read: Marvel Studios’ THUNDERBOLTS: Everything You Need to Know
Keep watching our YouTube Channel ‘DNP INDIA’. Also, please subscribe and follow us on FACEBOOK, INSTAGRAM, and TWITTER.
